CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
lovastatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000463
NCT00000463Phase 3Completed
CompareCT.gov

Post Coronary Artery Bypass Graft (CABG) Study

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Apr 14, 2016

In Brief

A Phase 3 clinical trial evaluating lovastatin, cholestyramine, and 1 other intervention for Cardiovascular Diseases and 3 related conditions. Completed.

Detailed Summary

To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Ischemia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
19871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartApr 1, 1987
Study CompletionDec 1, 1998
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

lovastatindrug

cholestyraminedrug

warfarindrug